Skip to main content
. 2014 Sep 23;111(11):2067–2075. doi: 10.1038/bjc.2014.494

Figure 4.

Figure 4

OS (from the start of the run-in period) for patients who did not develop grade ⩾2 rash during the 4-week run-in period who were randomised to receive standard therapy (gemcitabine plus erlotinib 100 mg per day) or dose escalation (gemcitabine plus escalating doses of erlotinib), compared with non-randomised patients who developed grade ⩾2 rash during the run-in period. Abbreviation: OS=overall survival.